Small Cell Lung Cancer Information Part 2
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
This article continues the series on small cell lung cancer (SCLC) treatment resources available in Japan. Recent advances in SCLC treatment include the approval of immunotherapy combinations such as atezolizumab (Tecentriq) plus chemotherapy and durvalumab (Imfinzi) plus chemotherapy in the first-line setting. Japanese clinical guidelines and hospital protocols continue to evolve as new data emerge from ongoing clinical trials. Medical Supporter provides guidance to help international patients access appropriate specialists and treatment facilities in Japan.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4